Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Azulene-based compounds for targeting orexin receptors.

Leino TO, Turku A, Yli-Kauhaluoma J, Kukkonen JP, Xhaard H, Wallén EAA.

Eur J Med Chem. 2018 Jul 20;157:88-100. doi: 10.1016/j.ejmech.2018.07.040. [Epub ahead of print]

PMID:
30077889
2.

Stapled truncated orexin peptides as orexin receptor agonists.

Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA.

Peptides. 2018 Apr;102:54-60. doi: 10.1016/j.peptides.2018.02.004. Epub 2018 Feb 21.

3.

Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell-Cell Contact - Role of mGluR5 and TRPC3 Channels.

Turunen PM, Louhivuori LM, Louhivuori V, Kukkonen JP, Åkerman KE.

Neuroscience. 2018 Apr 1;375:135-148. doi: 10.1016/j.neuroscience.2018.02.005. Epub 2018 Feb 10.

PMID:
29438802
4.

Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics.

Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP.

Pharmaceuticals (Basel). 2017 Oct 8;10(4). pii: E79. doi: 10.3390/ph10040079.

5.

BAT is independently affected by peripheral and central pathways.

Kukkonen JP.

Int J Obes (Lond). 2018 Mar;42(3):584. doi: 10.1038/ijo.2017.221. No abstract available.

PMID:
28883540
6.

Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity.

Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP.

PLoS One. 2017 Jun 2;12(6):e0178526. doi: 10.1371/journal.pone.0178526. eCollection 2017.

7.

Orexin/Hypocretin Signaling.

Kukkonen JP.

Curr Top Behav Neurosci. 2017;33:17-50. doi: 10.1007/7854_2016_49. Review.

PMID:
27909990
8.

Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands.

Turku A, Borrel A, Leino TO, Karhu L, Kukkonen JP, Xhaard H.

J Med Chem. 2016 Sep 22;59(18):8263-75. doi: 10.1021/acs.jmedchem.6b00333. Epub 2016 Sep 8.

PMID:
27546834
9.

G-protein-dependency of orexin/hypocretin receptor signalling in recombinant Chinese hamster ovary cells.

Kukkonen JP.

Biochem Biophys Res Commun. 2016 Aug 5;476(4):379-385. doi: 10.1016/j.bbrc.2016.05.130. Epub 2016 May 26.

PMID:
27237973
10.

p75 Neurotrophin Receptor Signaling Activates Sterol Regulatory Element-binding Protein-2 in Hepatocyte Cells via p38 Mitogen-activated Protein Kinase and Caspase-3.

Pham DD, Do HT, Bruelle C, Kukkonen JP, Eriksson O, Mogollón I, Korhonen LT, Arumäe U, Lindholm D.

J Biol Chem. 2016 May 13;291(20):10747-58. doi: 10.1074/jbc.M116.722272. Epub 2016 Mar 16.

11.

Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons.

Mäkelä J, Tselykh TV, Kukkonen JP, Eriksson O, Korhonen LT, Lindholm D.

Neuropharmacology. 2016 Mar;102:266-75. doi: 10.1016/j.neuropharm.2015.11.020. Epub 2015 Nov 26.

PMID:
26631533
12.

G-protein inhibition profile of the reported Gq/11 inhibitor UBO-QIC.

Kukkonen JP.

Biochem Biophys Res Commun. 2016 Jan 1;469(1):101-107. doi: 10.1016/j.bbrc.2015.11.078. Epub 2015 Nov 22.

PMID:
26614908
13.

OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells.

Kukkonen JP.

Cell Signal. 2016 Feb;28(2):51-60. doi: 10.1016/j.cellsig.2015.11.009. Epub 2015 Nov 12.

PMID:
26582739
14.

Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery.

Putula J, Pihlajamaa T, Kukkonen JP.

Br J Pharmacol. 2014 Dec;171(24):5816-28. doi: 10.1111/bph.12883. Epub 2014 Nov 5.

15.

OX1 and OX2 orexin/hypocretin receptor pharmacogenetics.

Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP.

Front Neurosci. 2014 May 6;8:57. doi: 10.3389/fnins.2014.00057. eCollection 2014. Review.

16.

Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors.

Jäntti MH, Mandrika I, Kukkonen JP.

Biochem Biophys Res Commun. 2014 Mar 7;445(2):486-90. doi: 10.1016/j.bbrc.2014.02.026. Epub 2014 Feb 13.

PMID:
24530395
17.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

18.

Orexin/hypocretin receptor signalling cascades.

Kukkonen JP, Leonard CS.

Br J Pharmacol. 2014 Jan;171(2):314-31. doi: 10.1111/bph.12324. Review.

19.

Orexin/hypocretin receptor signalling: a functional perspective.

Leonard CS, Kukkonen JP.

Br J Pharmacol. 2014 Jan;171(2):294-313. doi: 10.1111/bph.12296.

20.

Lipid signaling cascades of orexin/hypocretin receptors.

Kukkonen JP.

Biochimie. 2014 Jan;96:158-65. doi: 10.1016/j.biochi.2013.06.015. Epub 2013 Jun 28. Review.

PMID:
23810911
21.

Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling.

Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP.

Mol Pharmacol. 2013 Mar;83(3):621-32. doi: 10.1124/mol.112.080523. Epub 2012 Dec 11.

22.

Physiology of the orexinergic/hypocretinergic system: a revisit in 2012.

Kukkonen JP.

Am J Physiol Cell Physiol. 2013 Jan 1;304(1):C2-32. doi: 10.1152/ajpcell.00227.2012. Epub 2012 Oct 3. Review.

23.

Recent progress in orexin/hypocretin physiology and pharmacology.

Kukkonen JP.

Biomol Concepts. 2012 Oct;3(5):447-63. doi: 10.1515/bmc-2012-0013.

PMID:
25436549
24.

Communication between the calcium and cAMP pathways regulate the expression of the TSH receptor: TRPC2 in the center of action.

Löf C, Sukumaran P, Viitanen T, Vainio M, Kemppainen K, Pulli I, Näsman J, Kukkonen JP, Törnquist K.

Mol Endocrinol. 2012 Dec;26(12):2046-57. doi: 10.1210/me.2012-1171. Epub 2012 Sep 26.

25.

OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release.

Turunen PM, Jäntti MH, Kukkonen JP.

Mol Pharmacol. 2012 Aug;82(2):156-67. doi: 10.1124/mol.112.078063. Epub 2012 May 1.

26.

International symposium on G-protein-coupled receptors (GPCRs), TRP (ion) channels and lipid signalling - GPCR-Helsinki 2010.

Kukkonen JP.

Acta Physiol (Oxf). 2012 Feb;204(2):148-50. doi: 10.1111/j.1748-1716.2011.02393.x. No abstract available.

PMID:
22222216
27.

Mapping of the binding sites for the OX1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras.

Putula J, Kukkonen JP.

Neurosci Lett. 2012 Jan 6;506(1):111-5. doi: 10.1016/j.neulet.2011.10.061. Epub 2011 Nov 2.

PMID:
22079339
28.

Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus.

Putkonen N, Kukkonen JP, Mudo G, Putula J, Belluardo N, Lindholm D, Korhonen L.

Eur J Neurosci. 2011 Oct;34(8):1212-21. doi: 10.1111/j.1460-9568.2011.07858.x. Epub 2011 Oct 7.

PMID:
21978141
29.

OX1 orexin/hypocretin receptor activation of phospholipase D.

Jäntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP.

Br J Pharmacol. 2012 Feb;165(4b):1109-23. doi: 10.1111/j.1476-5381.2011.01565.x.

30.

A ménage à trois made in heaven: G-protein-coupled receptors, lipids and TRP channels.

Kukkonen JP.

Cell Calcium. 2011 Jul;50(1):9-26. doi: 10.1016/j.ceca.2011.04.005. Epub 2011 May 25. Review.

PMID:
21616532
31.

Adrenoceptor activity of muscarinic toxins identified from mamba venoms.

Näreoja K, Kukkonen JP, Rondinelli S, Toivola DM, Meriluoto J, Näsman J.

Br J Pharmacol. 2011 Sep;164(2b):538-50. doi: 10.1111/j.1476-5381.2011.01468.x.

32.

Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction.

Putula J, Turunen PM, Johansson L, Näsman J, Ra R, Korhonen L, Kukkonen JP.

FEBS Lett. 2011 May 6;585(9):1368-74. doi: 10.1016/j.febslet.2011.04.020. Epub 2011 Apr 15.

33.

Agonist ligand discrimination by the two orexin receptors depends on the expression system.

Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP.

Neurosci Lett. 2011 Apr 20;494(1):57-60. doi: 10.1016/j.neulet.2011.02.055. Epub 2011 Mar 6.

PMID:
21362456
34.

Filtration assay for arachidonic acid release.

Turunen PM, Putula J, Kukkonen JP.

Anal Biochem. 2010 Dec 15;407(2):233-6. doi: 10.1016/j.ab.2010.07.014. Epub 2010 Jul 23.

PMID:
20655865
35.

Octopamine receptors from the barnacle balanus improvisus are activated by the alpha2-adrenoceptor agonist medetomidine.

Lind U, Alm Rosenblad M, Hasselberg Frank L, Falkbring S, Brive L, Laurila JM, Pohjanoksa K, Vuorenpää A, Kukkonen JP, Gunnarsson L, Scheinin M, Mårtensson Lindblad LG, Blomberg A.

Mol Pharmacol. 2010 Aug;78(2):237-48. doi: 10.1124/mol.110.063594. Epub 2010 May 20.

36.

Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death.

Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kairisalo M, Takei N, Lindholm D, Korhonen L.

Cell Mol Life Sci. 2010 Jun;67(11):1929-41. doi: 10.1007/s00018-010-0305-y. Epub 2010 Mar 17.

PMID:
20232225
37.

Arachidonic acid release mediated by OX1 orexin receptors.

Turunen PM, Ekholm ME, Somerharju P, Kukkonen JP.

Br J Pharmacol. 2010 Jan;159(1):212-21. doi: 10.1111/j.1476-5381.2009.00535.x. Epub 2009 Dec 4.

38.

NF-kappaB-dependent regulation of brain-derived neurotrophic factor in hippocampal neurons by X-linked inhibitor of apoptosis protein.

Kairisalo M, Korhonen L, Sepp M, Pruunsild P, Kukkonen JP, Kivinen J, Timmusk T, Blomgren K, Lindholm D.

Eur J Neurosci. 2009 Sep;30(6):958-66. doi: 10.1111/j.1460-9568.2009.06898.x. Epub 2009 Sep 4.

PMID:
19735291
39.

Rapid and easy semi-quantitative evaluation method for diacylglycerol and inositol-1,4,5-trisphosphate generation in orexin receptor signalling.

Ekholm ME, Johansson L, Kukkonen JP.

Acta Physiol (Oxf). 2010 Mar;198(3):387-92. doi: 10.1111/j.1748-1716.2009.02017.x. Epub 2009 Jul 6.

PMID:
19583704
40.

Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptors.

Peltonen HM, Magga JM, Bart G, Turunen PM, Antikainen MS, Kukkonen JP, Akerman KE.

Biochem Biophys Res Commun. 2009 Jul 31;385(3):408-12. doi: 10.1016/j.bbrc.2009.05.077. Epub 2009 May 21.

PMID:
19464259
41.

An easy ratiometric compensation for the extracellular Ca2+ indicator-caused fluorescence artifact.

Kukkonen JP.

Anal Biochem. 2009 Jul 15;390(2):212-4. doi: 10.1016/j.ab.2009.04.017. Epub 2009 Apr 17.

PMID:
19376081
42.

Sequence features of HLA-DRB1 locus define putative basis for gene conversion and point mutations.

von Salomé J, Kukkonen JP.

BMC Genomics. 2008 May 19;9:228. doi: 10.1186/1471-2164-9-228.

43.

Multiple phospholipase activation by OX(1) orexin/hypocretin receptors.

Johansson L, Ekholm ME, Kukkonen JP.

Cell Mol Life Sci. 2008 Jun;65(12):1948-56. doi: 10.1007/s00018-008-8206-z.

PMID:
18488139
44.

IP3-independent signalling of OX1 orexin/hypocretin receptors to Ca2+ influx and ERK.

Ekholm ME, Johansson L, Kukkonen JP.

Biochem Biophys Res Commun. 2007 Feb 9;353(2):475-80. Epub 2006 Dec 15.

PMID:
17188243
45.

Regulation of OX1 orexin/hypocretin receptor-coupling to phospholipase C by Ca2+ influx.

Johansson L, Ekholm ME, Kukkonen JP.

Br J Pharmacol. 2007 Jan;150(1):97-104. Epub 2006 Nov 20.

46.

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

Magga J, Bart G, Oker-Blom C, Kukkonen JP, Akerman KE, Näsman J.

Biochem Pharmacol. 2006 Mar 14;71(6):827-36. Epub 2006 Jan 20.

PMID:
16430869
47.

G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase.

Ammoun S, Lindholm D, Wootz H, Akerman KE, Kukkonen JP.

J Biol Chem. 2006 Jan 13;281(2):834-42. Epub 2005 Nov 10.

48.

OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling.

Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Akerman KE, Kukkonen JP.

Mol Endocrinol. 2006 Jan;20(1):80-99. Epub 2005 Sep 1.

PMID:
16141359
49.
50.

Origin of the prolactin-releasing hormone (PRLH) receptors: evidence of coevolution between PRLH and a redundant neuropeptide Y receptor during vertebrate evolution.

Lagerström MC, Fredriksson R, Bjarnadóttir TK, Fridmanis D, Holmquist T, Andersson J, Yan YL, Raudsepp T, Zoorob R, Kukkonen JP, Lundin LG, Klovins J, Chowdhary BP, Postlethwait JH, Schiöth HB.

Genomics. 2005 Jun;85(6):688-703.

PMID:
15885496

Supplemental Content

Loading ...
Support Center